Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Research

Lower serum expression of miR-181c-5p is associated with increased plasma levels of amyloid-beta 1–40 and cerebral vulnerability in normal aging

Authors: Marta Manzano-Crespo, Mercedes Atienza, Jose L. Cantero

Published in: Translational Neurodegeneration | Issue 1/2019

Login to get access

Abstract

Background

Previous studies have shown that expression levels of miR-181c are downregulated by amyloid-β (Aβ) deposition and chronic cerebral hypoperfusion, both factors largely associated with the development of AD. Moreover, reduced 2-[18F]fluoro-2-deoxy-D-glucose (FDG)-PET brain metabolism and volume loss of regions of the medial temporal lobe have been generally recognized as hallmarks of AD. Based on this evidence, we have here investigated potential associations between serum levels of miR-181c-5p and these AD signatures in asymptomatic elderly subjects.

Methods

Ninety-five normal elderly subjects underwent clinical, cognitive, structural MRI, and FDG-PET explorations. Serum expression levels of miR-181c-5p and plasma Aβ concentrations were further analyzed in this cohort. Regression analyses were performed to assess associations between serum miR-181c-5p levels and cognitive functioning, plasma Aβ, structural and metabolic brain changes.

Results

Decreased serum expression of miR-181c-5p was associated with increased plasma levels of Aβ1–40, deficits in cortical glucose metabolism, and volume reduction of the entorhinal cortex. No significant associations were found between lower miR-181c-5p levels and cognitive deficits or cortical thinning.

Conclusions

These findings suggest that deregulation of serum miR-181c-5p may indicate cerebral vulnerability in late life.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–42.CrossRefPubMedPubMedCentral
4.
Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201–4.PubMedPubMedCentralCrossRef
5.
Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, et al. Rapamycin slows aging in mice. Aging Cell. 2012;11:675–82.PubMedCrossRef
6.
Blagosklonny MV. Disease or not, aging is easily treatable. Aging (Albany NY). 2018;10:3067–78.CrossRef
7.
Partridge L. Intervening in ageing to prevent the diseases of ageing. Trends Endocrinol Metab. 2014;25:555–7.PubMedCrossRef
8.
9.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.PubMedPubMedCentralCrossRef
10.
11.
Dehghani R, Rahmani F, Rezaei N. MicroRNA in Alzheimer’s disease revisited: implications for major neuropathological mechanisms. Rev Neurosci. 2018;29:161–82.PubMedCrossRef
12.
Tan L, Yu JT, Liu QY, Tan MS, Zhang W, Hu N, et al. Circulating miR-125b as a biomarker of Alzheimer’s disease. J Neurol Sci. 2014;336:52–6.PubMedCrossRef
13.
Nagaraj S, Laskowska-Kaszub K, Dębski KJ, Wojsiat J, Dąbrowski M, Gabryelewicz T, et al. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects. Oncotarget. 2017;8:16122–43.PubMedPubMedCentralCrossRef
14.
Dong H, Li J, Huang L, Chen X, Li D, Wang T, et al. Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer’s disease. Dis Markers. 2015;2015:625659.PubMedPubMedCentral
15.
Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, et al. Circulating miRNAs as potential biomarkers in Alzheimer’s disease. J Alzheimers Dis. 2014;42:1261–7.PubMedCrossRef
16.
Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14:R78.PubMedPubMedCentralCrossRef
17.
Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol. 2012;235:491–6.PubMedCrossRef
18.
19.
Schonrock N, Humphreys DT, Preiss T, Götz J. Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. J Mol Neurosci. 2012;46:324–35.PubMedCrossRef
20.
Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, et al. Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. PLoS One. 2010;5(6):e11070.PubMedPubMedCentralCrossRef
21.
Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14:27–41.PubMedCrossRef
22.
Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer’s disease. J Neurosci. 2011;31:14820–30.PubMedPubMedCentralCrossRef
23.
Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation. PLoS One. 2010;52(2):e8898.CrossRef
24.
Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H, et al. A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2017;60:1365–77.PubMedCrossRef
25.
Siedlecki-Wullich D, Català-Solsona J, Fábregas C, Hernández I, Clarimon J, Lleó A, et al. Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease. Alzheimers Res Ther. 2019;11(1):46.PubMedPubMedCentralCrossRef
26.
Böhm P, Peña-Casanova J, Aguilar M, Hernandez G, Sol JM, Blesa R, et al. Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities. Int Psychogeriatr. 1998;10:261–70.PubMedCrossRef
27.
Yesavage JA, Brink TL, Rose TL, Lum O. Development and validation of a geriatric depression scale: a preliminary report. J Psychiat Res. 1983;17:37–49.CrossRef
28.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed
29.
Maldonado-Lasuncion I, Atienza M, Sanchez-Espinosa MP, Cantero JL. Aging-related changes in cognition and cortical integrity are associated with serum expression of candidate microRNAs for Alzheimer disease. Cereb Cortex. 2019;29(10):4426–37.PubMedCrossRef
30.
31.
Bernal-Rusiel JL, Atienza M, Cantero JL. Detection of focal changes in human cortical thickness: spherical wavelets versus Gaussian smoothing. Neuroimage. 2008;41:1278–92.PubMedCrossRef
32.
Park HJ, Lee JD, Chun JW, Seok JH, Yun M, Oh MK, et al. Cortical surface-based analysis of 18F-FDG PET: measured metabolic abnormalities in schizophrenia are affected by cortical structural abnormalities. Neuroimage. 2006;31:1434–44.PubMedCrossRef
33.
Destrieux C, Fischl B, Dale A, Halgren E. Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage. 2010;53:1–15.PubMedCrossRef
34.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.PubMedCrossRef
35.
Bernal-Rusiel JL, Atienza M, Cantero JL. Determining the optimal level of smoothing in cortical thickness analysis: a hierarchical approach based on sequential statistical thresholding. Neuroimage. 2010;52:158–71.PubMedCrossRef
36.
Bludau S, Eickhoff SB, Mohlberg H, Caspers S, Laird AR, Fox PT, et al. Cytoarchitecture, probability maps and functions of the human frontal pole. Neuroimage. 2014;93:260–75.PubMedCrossRef
37.
Ding SL, Van Hoesen GW, Cassell MD, Poremba A. Parcellation of human temporal polar cortex: a combined analysis of multiple cytoarchitectonic, chemoarchitectonic, and phthological markers. J Comp Neurol. 2009;514:595–623.PubMedPubMedCentralCrossRef
38.
McDonald B, Highley JR, Walker MA, Herron BM, Cooper SJ, Esiri MM, et al. Anomalous asymmetry of fusiform and parahipocampal gyrus gray matter in schizophrenia: a postmortem study. Am J Psychiatry. 2000;157:40–7.PubMedCrossRef
39.
Malikovic A, Amunts K, Schleicher A, Mohlberg H, Kujovic M, Palomero-Gallagher N, et al. Cytoarchitecture of the human lateral occipital cortex: mapping of two extrastriate areas hOc4la and hOc4lp. Brain Struct Funct. 2016;221:1877–97.PubMedCrossRef
40.
Scheperjans F, Eickhoff SB, Hömke H, Mohlberg K, Hermann K, Amunts K, et al. Probabilistic maps, morphometry, and variability of citoarchitectonic areas in the human superior parietal cortex. Cereb Cortex. 2008;18:2141–57.PubMedPubMedCentralCrossRef
41.
Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14:639–52.PubMedPubMedCentralCrossRef
42.
Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta. 1862;2016:1617–27.
43.
44.
Fang C, Li Q, Min G, Liu M, Cui J, Sun J, et al. MicroRNA-181c ameliorates cognitive impairment induced by chronic cerebral hypoperfusion in rats. Mol Neurobiol. 2017;54:8370–85.PubMedCrossRef
45.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med. 1996;2:864–70.PubMedCrossRef
46.
Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology. 1997;48:741–5.PubMedCrossRef
47.
Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, et al. Elevated plasma beta-amyloid peptide Abeta (42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64:1007–13.PubMedPubMedCentralCrossRef
48.
Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, et al. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis. 2011;23:399–409.PubMedPubMedCentralCrossRef
49.
Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70:596–606.PubMedCrossRef
50.
Llado-Saz S, Atienza M, Cantero JL. Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects. Neurobiol Aging. 2015;36:2791–7.PubMedCrossRef
51.
van Leijsen EMC, Kuiperij HB, Kersten I, Bergkamp MI, van Uden IWM, Vanderstichele H, et al. Plasma Aβ (Amyloid-β) levels and severity and progression of small vessel disease. Stroke. 2018;49:884–90.PubMedCrossRef
52.
Gomis M, Sobrino T, Ois A, Millán M, Rodríguez-Campello A, Pérez de la Ossa N, et al. Plasma beta-amyloid 1–40 is associated with the diffuse small vessel disease subtype. Stroke. 2009;40:3197–201.PubMedCrossRef
53.
54.
Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, et al. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry. 2015;20:1188–96.PubMedCrossRef
55.
Wei H, Xu Y, Xu W, Zhou Q, Chen Q, Yang M, et al. Serum exosomal miR-223 serves as a potential diagnostic and prognostic biomarker for dementia. Neuroscience. 2018;379:167–76.PubMedCrossRef
56.
Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, et al. Glucose metabolism in early onset versus late onset Alzheimer’s disease: an SPM analysis of 120 patients. Brain. 2005;128:1790–801.PubMedCrossRef
57.
Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36:811–22.PubMedPubMedCentralCrossRef
58.
Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin. 2013;4:45–52.PubMedPubMedCentralCrossRef
59.
Zhang L, Li YJ, Wu XY, Hong Z, Wei WS. MicroRNA-181c negatively regulates the inflammatory response in oxygen-glucose-deprived microglia by targeting toll-like receptor 4. J Neurochem. 2015;132:713–23.PubMedCrossRef
60.
Zilberter Y, Zilberter M. The vicious circle of hypometabolism in neurodegenerative diseases: ways and mechanisms of metabolic correction. J Neurosci Res. 2017;95:2217–35.PubMedCrossRef
61.
Zhou H, Zhang R, Lu K, Yu W, Xie B, Cui D, et al. Deregulation of miRNA-181c potentially contributes to the pathogenesis of AD by targeting collapsin response mediator protein 2 in mice. J Neurol Sci. 2016;367:3–10.PubMedCrossRef
62.
Isono T, Yamashita N, Obara M, Araki T, Nakamura F, Kamiya Y, et al. Amyloid-β25–35 induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2. Neurosci Res. 2013;77:180–5.PubMedCrossRef
63.
Metadata
Title
Lower serum expression of miR-181c-5p is associated with increased plasma levels of amyloid-beta 1–40 and cerebral vulnerability in normal aging
Authors
Marta Manzano-Crespo
Mercedes Atienza
Jose L. Cantero
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2019
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-019-0174-8

Other articles of this Issue 1/2019

Translational Neurodegeneration 1/2019 Go to the issue

Research

Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43G298S ALS mouse model

Research

Loss of CREST leads to neuroinflammatory responses and ALS-like motor defects in mice

Research

Better survival in female SOD1-mutant patients with ALS: a study of SOD1-related natural history

Research

Xenografting of human umbilical mesenchymal stem cells from Wharton’s jelly ameliorates mouse spinocerebellar ataxia type 1

Review

How to spot ocular abnormalities in progressive supranuclear palsy? A practical review

Research

Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein